Join 44th JPM Healthcare Conference 2026 in San Francisco, CA, USA.

This premier conference is the largest and most informative healthcare investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
Health Community features the leading innovators and latest innovations from around the world which are addressing today’s health and wellness challenges. Learn how the latest advances, leading research and best practices are being applied to grow and scale digital health solutions.

Registration/ Hotel
Registration of J.P.M Healthcare Conference is for clients of the firm, by invitation only. Please reach out to your J.P.M representative to inquire about an invitation. Some company presentations will be available on their individual websites. The agenda is made available only to confirmed attendees.

J.P. M Healthcare Conference 2025: Comprehensive Updates

1. Conference Overview:

- Event Details: The 43rd Annual J.P. M Healthcare Conference is taking place in San Francisco from January 13–16, 2025. Renowned as the world’s largest healthcare investment symposium, it attracts key stakeholders in healthcare, biotech, and pharma industries.

- Attendance: Over 8,000 professionals, including executives, investors, and policymakers, are participating in this prestigious event.

- Economic Impact: The conference is expected to generate approximately $92 million for the city’s economy. The event significantly benefits hotels, restaurants, and other local businesses in San Francisco.

2. Major Deals and Announcements:

Johnson & Johnson (J&J) Acquires Intra-Cellular Therapies
- Announced a $14.6 billion acquisition of Intra-Cellular Therapies, known for its neuropsychiatric treatment, Caplyta.
- Strategic Focus: Expands J&J’s offerings in neuropsychology and treatments for mental health conditions like schizophrenia and bipolar disorder.

Eli Lilly Expands Oncology Portfolio
- Entered into a deal worth up to $2.5 billion to acquire experimental cancer therapy from Scorpion Therapeutics.
- Impact: Strengthens its position in oncology, targeting advanced therapies for difficult-to-treat cancers.

GSK Invests in Cancer Drug Development
- Announced the acquisition of IDRx, a Boston-based cancer drug developer, for up to $1.15 billion.
- Purpose: Focuses on oncology, aligning with GSK's broader goal of tackling complex cancer cases through innovative solutions.

AbbVie Secures Licensing for Blood Cancer Drug
- Partnered with Simcere Pharmaceutical to acquire licensing rights for a blood cancer drug in markets outside China.
- Deal Value: Estimated at up to $1.06 billion, with AbbVie aiming to strengthen its hematology portfolio.

3. Industry Sentiment and Challenges:

- Market Performance: The healthcare sector has underperformed in recent years:
  - Healthcare SPDR Fund grew only 3% since early 2023.
  - In contrast, the S&P 500 rose over 50%, highlighting challenges in investor confidence.

- Policy Uncertainty: Concerns loom over potential healthcare reforms under the Trump administration.
  - The controversial appointment of Robert F. Kennedy Jr., a known vaccine skeptic, as a top health official, has sparked debates.
  - Regulatory and funding uncertainties are top of mind for many executives.

- Security Concerns: Following recent incidents, including the tragic death of a UnitedHealth Group executive, security has been significantly increased at the conference. Measures include strict screening and monitoring to ensure participant safety.

4. Economic and Local Impact on San Francisco:

- Significant Economic Boost: The conference contributes approximately $92 million to San Francisco’s economy. Local businesses, including hotels and restaurants, see a substantial increase in revenue during the event.

- Support from Local Government: Mayor Daniel Lurie welcomed attendees and emphasized the city’s commitment to revitalization and safety. The event is part of broader efforts to showcase San Francisco as a hub for global business events and innovation.

5. Key Themes and Insights:

- Mergers and Acquisitions: Major companies are using the conference as a platform to announce high-value acquisitions and partnerships. Focus on expanding portfolios in oncology, neuropsychology, and hematology.

- Innovation and Research: Discussions center around emerging technologies and cutting-edge therapies, particularly in the fields of cancer and mental health.

- Cautious Optimism: While there is enthusiasm for innovation, policy and market challenges temper the overall sentiment.

Focus on AI at the J.P. Morgan Healthcare Conference 2025

1. AI in Drug Discovery and Development:

- Accelerating Drug Discovery: AI analyzes massive datasets to identify potential drug candidates more quickly and efficiently. Companies like Insilico Medicine and Exscientia are showcasing breakthroughs in AI-driven drug discovery pipelines.

- Personalized Medicine: AI models enable the development of therapies tailored to individual genetic profiles, improving treatment outcomes.

2. AI in Diagnostics:

- Early Detection of Diseases: AI-powered diagnostic tools identify diseases like cancer, cardiovascular conditions, and neurological disorders at early stages. Startups such as PathAI and Tempus are presenting innovations in AI-enabled pathology and genomics.

- Imaging and Radiology: AI systems improve the accuracy and speed of interpreting medical images, reducing diagnostic errors.

3. AI for Operational Efficiency:

- Hospital Management: AI solutions optimize workflows in hospitals, from scheduling and resource allocation to patient monitoring and data management.

- Supply Chain Management: AI predicts demand for medical supplies and ensures timely delivery, reducing costs and inefficiencies.

4. AI in Remote and Virtual Healthcare:

- Telemedicine and Virtual Assistants: AI-driven platforms enhance telemedicine by providing real-time patient data analysis and virtual health assistants to guide patient care.

- Wearables and Remote Monitoring: AI integrates with wearable devices to analyze health metrics and provide actionable insights for preventive care.

5. AI and Regulatory Compliance:

- Streamlining Compliance: AI tools assist pharmaceutical companies and healthcare providers in ensuring compliance with global regulatory standards. AI-driven analytics improve the quality of documentation and reporting processes.

6. AI Ethics and Data Privacy:

- Ethical AI Use: Discussions are centered on the responsible use of AI, focusing on eliminating biases in algorithms and ensuring equitable access to AI technologies.

- Data Security: With the increase in AI adoption, safeguarding patient data and adhering to privacy laws are critical concerns being addressed.

7. Keynote Discussions and Panels:

- “The Future of AI in Precision Medicine”: Featuring leading executives from AI-driven biotech firms.

- “Ethical AI in Healthcare”: Exploring how to mitigate biases and protect patient data while scaling AI solutions.

- “Investing in AI for Healthcare”: Focused on the financial landscape and ROI of AI investments in the sector.